That's a very good question. That is a really critical aspect of what we're hoping will happen as a result of CETA. That, as I mentioned earlier, is going to occur with regulatory changes that come under this patent-medicine notice-of-compliance regime. These regulations are incredibly powerful. They determine all of the infringement actions and the process. If you follow the pharmaceutical industry, you'll see that every new generic comes on the market after extensive litigation.
One of the concerns we've expressed with this bill is that we don't know what's in the regulations yet. In terms of the changes you're talking about to simplify the system, we have called for those. We've had some indication that the regulations are going to do that, but we haven't seen those regulations.